Innovation

Meyer Pharmaceuticals has selected INM-099E, a small molecule drug candidate, for further preclinical development. Recent preclinical studies of INM-089 demonstrated significant functional and pathological improvements in an AMD disease study model.

Results from several in vitro and in vivo studies demonstrate INM-089’s pharmacological effects in the potential treatment of dry AMD, as summarized:

INM-099E provides neuroprotection of photoreceptors and improves photoreceptor function
INM-099E improves the integrity of the retinal pigment epithelium (RPE)
INM-099E reduces extracellular autofluorescent (AF) deposits, a hallmark of dry AMD
INM-099E preserves retinal function in the back of the eye
INM-099E improves thickness of “outer nuclear layer” (ONL) of the retina where photoreceptors are located.
Based on widely accepted ocular research, the thickness of the outer nuclear layer is strongly correlated with photoreceptor preservation and visual acuity.

Meyer Pharmaceuticals is completing preclinical studies, including dose-ranging assessment studies, in preparation for a pre-IND meeting with the FDA in Q4 2026